Corcept Therapeutics (CORT) said Monday it presented phase 3 results from its Rosella trial at the American Society of Clinical Oncology annual meeting, showing that its investigational drug relacorilant, combined with nab-paclitaxel, improved outcomes for patients with platinum-resistant ovarian cancer.

The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease progression compared to chemotherapy alone, with median PFS rising to 6.5 months versus 5.5 months, the company said. An interim analysis also showed a 31% reduction in the risk of death, with overall survival extending to 16 months from 11.5 months.

The combination therapy was well-tolerated, with no increase in serious side effects. Patients on relacorilant had fewer complications such as ascites and abdominal paracenteses during treatment, Corcept Therapeutics said.

The global trial enrolled 381 patients across the U.S., Europe, South Korea, Brazil, Argentina, Canada and Australia, the company said.

Shares of Corcept were up more than 7% in recent trading.

Price: 83.62, Change: +6.05, Percent Change: +7.81